Evaluating a blood test for liver scarring and fat
Part of Digestive system, Hormones & metabolism clinical trials.
This trial checks how well the LIVERFASt blood test works compared to MRI scans for measuring liver scarring and fat buildup. It may help doctors use a simple blood test instead of expensive scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of fatty liver disease called MASLD or MetALD
- You have a past MRI scan that measured liver scarring
- You have a past LIVERFASt blood test result
- You do not have severe jaundice or recent very high liver enzymes
- You do not have other liver conditions that could affect test accuracy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new Liver Fibrosis Due to NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.